ENOXAPARIN SODIUM (PRESERVATIVE FREE): Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amphastar Pharm	ENOXAPARIN SODIUM (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	076684	ANDA	Amphastar Pharmaceuticals, Inc.	0548-5601-00	10 SYRINGE in 1 CARTON (0548-5601-00) / .3 mL in 1 SYRINGE	2011-09-19
Amphastar Pharm	ENOXAPARIN SODIUM (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	076684	ANDA	Amphastar Pharmaceuticals, Inc.	0548-5602-00	10 SYRINGE in 1 CARTON (0548-5602-00) / .4 mL in 1 SYRINGE	2011-09-19
Amphastar Pharm	ENOXAPARIN SODIUM (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	076684	ANDA	Amphastar Pharmaceuticals, Inc.	0548-5603-00	10 SYRINGE in 1 CARTON (0548-5603-00) / .6 mL in 1 SYRINGE	2011-09-19
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 2, 2025

Introduction

Enoxaparin Sodium, a low molecular weight heparin (LMWH), is a pivotal anticoagulant widely used in preventing and treating thromboembolic disorders. The preservative-free formulation of Enoxaparin Sodium addresses the needs of sensitive patient populations, including those with allergies or contraindications related to preservatives. The global demand for preservative-free Enoxaparin necessitates a robust supply chain comprising trusted manufacturers and suppliers. This report offers a detailed overview of the leading suppliers involved in the manufacturing and distribution of preservative-free Enoxaparin Sodium, emphasizing their production capabilities, regulatory compliance, and market positioning.

Manufacturers and Key Suppliers

1. Sanofi – LEO Pharma (Sanofi-Aventis)

Overview: Sanofi, one of the world's largest pharmaceutical companies, markets Enoxaparin under various brand names, including Lovenox. Historically, Sanofi has maintained a dominant position in producing high-quality Enoxaparin formulations, including preservative-free variants.

Supply Capabilities: Sanofi's manufacturing facilities adhere to stringent Good Manufacturing Practice (GMP) standards, ensuring high purity and efficacy. The company has a global distribution network capable of meeting the international demand for preservative-free Enoxaparin.

Regulatory Compliance: As a U.S. FDA-approved and EMA-compliant manufacturer, Sanofi maintains rigorous quality controls and documentation, facilitating approval and supply across multiple regions.

Market Presence: Sanofi's entrenched market presence, backed by extensive R&D, makes it a primary supplier for preservative-free Enoxaparin Sodium globally.

2. Baxter International Inc.

Overview: Baxter specializes in biopharmaceuticals and sterile injectable products, including low molecular weight heparins. The company offers preservative-free formulations tailored for sensitive patients, especially in hospital and outpatient settings.

Supply Capabilities: Baxter’s manufacturing units employ state-of-the-art aseptic processing and sterilization, ensuring preservative-free, high-purity Enoxaparin products. Their global logistics facilitate widespread availability.

Regulatory Compliance: Baxter’s products are approved by major regulatory bodies, including the FDA, EMA, and PMDA Japan, underscoring their commitment to quality standards required for preservative-free injectable drugs.

3. Sandoz (Novartis Group)

Overview: Sandoz, Novartis' generics division, is a significant player in producing biosimilar and generic injectable medicines, including low molecular weight heparins like Enoxaparin Sodium.

Supply Capabilities: Sandoz manufactures preservative-free Enoxaparin in compliance with international standards, leveraging innovative sterile production techniques to ensure product safety and stability.

Regulatory Compliance: Sandoz’s products undergo strict regulatory review across jurisdictions, ensuring that preservative-free formulations meet the necessary safety and efficacy benchmarks.

Market Focus: Sandoz actively markets preservative-free Enoxaparin to hospitals and clinics globally, emphasizing affordability without compromising quality.

4. Accord Healthcare

Overview: Accord Healthcare is a prominent global generics manufacturer with a growing portfolio of injectable anticoagulants. Their focus on quality, affordability, and compliance positions them as a key supplier.

Supply Capabilities: The company produces preservative-free Enoxaparin Sodium under GMP conditions, with flexible supply chains targeting emerging markets and developed regions.

Regulatory Status: Accord’s products hold approvals from major agencies like the FDA, NHS registration in the UK, and approval from the EMA, ensuring reliable supply of preservative-free formulations.

5. Cipla Limited

Overview: Cipla is a leading Indian pharmaceutical firm with a reputation for producing affordable, high-quality injectable medicines, including LMWHs.

Supply Capabilities: Cipla manufactures preservative-free Enoxaparin Sodium using high-quality sterile processing techniques, supplied to domestic and select international markets.

Regulatory Compliance: Cipla’s manufacturing units are compliant with US FDA and EMA standards, facilitating export to regulated markets.

Emerging and Niche Suppliers

Mylan (Now part of Viatris): Offers generic preservative-free Enoxaparin Sodium, primarily catering to the European and Asian markets, with expansion plans for broader regions.
Zydus Cadila: An Indian pharmaceutical company expanding its injectable anticoagulants portfolio, including preservative-free formulations, with a focus on cost-effective supply.

Regulatory and Quality Considerations

Manufacturers supplying preservative-free Enoxaparin Sodium must adhere to strict regulatory frameworks to ensure product safety, efficacy, and stability. The choice of supplier often hinges on their GMP compliance, certification (such as ISO 13485), and market approval status. International standards like those established by the World Health Organization (WHO) and respective regional agencies (FDA, EMA, MHRA) underpin supplier credibility.

Market Dynamics and Supply Chain Factors

Global Demand: The rising prevalence of cardiovascular and thromboembolic diseases sustains high demand for Enoxaparin Sodium, including its preservative-free variants.
Production Challenges: Ensuring sterility and preservative-free formulation necessitates advanced aseptic processing and rigorous quality control, limiting the number of reliable suppliers.
Supply Chain Risks: Concentration among major manufacturers like Sanofi and Baxter increases dependency risks; recent geopolitical, logistical, and pandemic-related disruptions have accentuated supply chain vulnerabilities.

Conclusion

A robust supply chain for preservative-free Enoxaparin Sodium involves leading multinational manufacturers like Sanofi, Baxter, Sandoz, Accord Healthcare, and Cipla. These companies emphasize high-quality sterile manufacturing processes, regulatory compliance, and wide geographic distribution. Buyers should prioritize suppliers with proven GMP adherence, comprehensive regulatory approvals, and capacity for scalable production to mitigate risks and ensure consistent drug availability.

Key Takeaways

Trusted Suppliers Are Critical: Sanofi and Baxter dominate the preservative-free Enoxaparin Sodium market, offering reliable supply and regulatory assurance.
Regulatory Compliance Is Paramount: Ensure suppliers meet regional standards (FDA, EMA) to minimize approval risks.
Quality over Cost: While generic options like Cipla and Accord offer affordability, verification of sterile manufacturing practices is essential.
Supply Chain Resilience: Diversification among multiple suppliers reduces dependency risks amid global disruptions.
Innovation and Capacity Expansion: Emerging players like Zydus and Mylan are expanding offerings, providing strategic options for buyers.

FAQs

1. Are there any regional restrictions on prescribing preservative-free Enoxaparin Sodium?
Preservative-free formulations are generally approved globally; however, availability may vary based on regional regulatory approvals. Always verify local authorization before procurement.

2. How does the manufacturing process ensure the sterility of preservative-free Enoxaparin?
Manufacturers utilize advanced aseptic processing, sterile filtration, and validated sterilization techniques to maintain product sterility without preservatives.

3. What should clinicians consider when selecting a supplier for preservative-free Enoxaparin?
Clinicians should prioritize suppliers with regulatory approvals (FDA, EMA), GMP compliance, proven stability data, and reliable distribution networks.

4. Is generic preservative-free Enoxaparin as effective as branded versions?
Yes, approved generics undergo rigorous bioequivalence testing, confirming comparable efficacy, safety, and quality.

5. What are the risks associated with supply chain disruptions for Enoxaparin?
Disruptions may lead to shortages, impacting patient care. Diversifying suppliers and maintaining safety stock are vital mitigation strategies.

Sources

[1] Sanofi official website and product documentation.
[2] Baxter International - Product portfolio and manufacturing standards.
[3] Sandoz (Novartis) regulatory filings and product approvals.
[4] Accord Healthcare manufacturing and quality certifications.
[5] Cipla corporate documentation and international approvals.

Suppliers and packagers for ENOXAPARIN SODIUM (PRESERVATIVE FREE)